Strategies for tolerance induction in nonhuman primates

Annals of Plastic Surgery

Volumn 55, Issue 5, 2005, Pages 545-553

  Siemionow, Maria ^a   Unal, Sakir ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Composite tissue allografts; Nonhuman primates; Tolerance; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHIMERA; COMPOSITE GRAFT; CONTROLLED STUDY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; NONHUMAN; ORGAN TRANSPLANTATION; PLASTIC SURGERY; PRIMATE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SURGICAL TECHNIQUE; T LYMPHOCYTE ACTIVATION; TISSUE GRAFT;

ANIMALS; HEART TRANSPLANTATION; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; PRIMATES; SKIN; SKIN TRANSPLANTATION; TISSUE TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 27644512821     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000182657.35457.8b     Document Type: Review

References (93)

1. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet. 1999;353:1315-1320.
2. Jones JW, Gruber SA, Barker JH, et al. Successful hand transplantation: one-year follow-up: Louisville Hand Transplant Team. N Engl J Med. 2000;343:468-473.
3. Francois CG, Breidenbach WC, Maldonado C, et al. Hand transplantation: comparisons and observations of the first four clinical cases. Microsurgery. 2000;20:360-371.
4. Lanzetta M, Petruzzo P, Vitale G, et al. Human hand transplantation: what have we learned? Transplant Proc. 2004;36:664-668.
5. Levi DM, Tzakis AG, Kato T, et al. Transplantation of the abdominal wall. Lancet. 2003;36:2173-2176.
6. Hofmann GO, Kirschner MH, Wagner FD, et al. Allogeneic vascularized transplantation of human femoral diaphyses and total knee joints first clinical experiences. Transplant Proc. 1998;30:2754-2761.
7. Mackinnon SE, Doolabh VB, Novak CB, et al. Clinical outcome following nerve allograft transplantation. Plast Reconstr Surg. 2001;107:1419-1429.
8. Guimberteau JC, Baudet J, Panconi B, et al. Human allotransplant of a digital flexion system vascularized on the ulnar pedicle: a preliminary report and 1-year follow-up of two cases. Plast Reconstr Surg. 1992;89:1135-1147.
9. Rose KG, Sesterhenn K, Wustrow F. Tracheal allotransplantation in man. Lancet. 1979;1:433.
10. Levashow YN, Yablonsky PK, Cherny SM, et al. One stage allotransplantation of thoracic segment of the trachea in a patient with idiopathic fibrosing mediastinitis and marked tracheal stenosis. Eur J Cardiothorac Surg. 1993;7:383-386.
11. Strome M. Human laryngeal transplantation: considerations and implications. Microsurgery. 2000;20:372-374.
12. Jones TR, Humphrey PA, Brennan DC. Transplantation of vascularized allogeneic skeletal muscle for scalp reconstruction in renal transplant patient. Transplant Proc. 1998;30:2746-2753.
13. Birchall M. Tongue transplantation. Lancet. 2004;363:1663.
14. Jiang HQ, Wang Y, Hu XB, et al. Composite tissue allograft transplantation of cephalocervical skin flap and two ears. Plast Reconstr Surg. 2005;115:31e-35e.
15. Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med. 1994;61:308-313.
16. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther. 1996;34:515-519.
17. Dunn DL. Problems related to immunosuppression: infection and malignancy occurring after solid organ transplantation. Crit Care Clin. 1990;6:955-977.
18. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol. 1996;8:710-720.
19. Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999;21:1632-1652.
20. Geluk A, Elferink DG, Slierendregt BL, et al. Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates. J Exp Med. 1993;177:979-987.
21. Hewitt CW, Black KS, Fraser LA, et al. Composite tissue (limb) allografts in rats, I: dose-dependent increase in survival with cyclosporine. Transplantation. 1985;39:360-364.
22. Arai K, Hotokebuchi T, Miyahara H, et al. Limb allografts in rats immunosuppressed with FK506, I: Reversal of rejection and indefinite survival. Transplantation. 1989;48:782-786.
23. Buttemeyer R, Jones NF, Min Z, et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. Plast Reconstr Surg. 1996;97:139-148.
24. Inceoglu S, Siemionow M, Chick L, et al. The effect of combined immunosuppression with systemic low-dose cyclosporine and topical fluocinolone acetonide on the survival of rat hind-limb allografts. Ann Plast Surg. 1994;33:57-65.
25. Siemionow M, Oke R, Ozer K, et al. Induction of donor-specific tolerance in rat hind-limb allografts under antilymphocyte serum and cyclosporine A protocol. J Hand Surg [Am]. 2002;27:1095-1103.
26. Siemionow M, Gozel-Ulusal B, Engin Ulusal A, et al. Functional tolerance following face transplantation in the rat. Transplantation. 2003;75:1607-1609.
27. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. Lancet. 1992;27:339:1579-1582.
28. Prabhune KA, Gorantla VS, Maldonado C, et al. Mixed allogeneic chimerism and tolerance to composite tissue allografts. Microsurgery. 2000;20:441-447.
29. Ishida H, Kawai T, Tanabe K, et al. Status of microchimerism in recipients 15 years after living related kidney transplantation. Transplantation. 1996;62:126-128.
30. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allograft or xenografts. Nature. 1984;307:168-170.
31. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med. 1989;169:493-502.
32. Fuchimoto Y, Huang CA, Yamada K, et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest. 2000;105:1779-1789.
33. Sachs DH. Mixed chimerism as an approach to transplantation tolerance. Clin Immunol. 2000;95:S63-S68.
34. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogenic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation. 1995;59:256-262.
35. Kawai T, Poncelet A, Sachs DH, et al. Long-term outcome and allobody production in a nonmyeloablative regimen for induction of renal allograft tolerance. Transplantation. 1999;68:1767-1775.
36. Kimikawa M, Sachs DH, Colvin RB, et al. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation. 1997;64:709-716.
37. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation. 1999;68:480-484.
38. Jonker M, van den Hout Y, Noort RC, et al. Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. Transplantation. 2001;72:1432-1436.
39. van Vreeswijk W, Balner H. Major histocompatibility complex matching and other factors influencing skin allograft survival in related and unrelated rhesus monkeys. Transplantation. 1980;30:196-202.
40. Young KJ, Yang L, Phillips MJ, et al. Donor-lymphocyte infusion induces transplantation tolerance by activating systemic and graft-infiltrating double-negative regulatory T-cells. Blood. 2002;100:3408-3414.
41. Sykes M. Mixed chimerisms and transplant tolerance. Immunity. 2001;14:417-424.
42. De Wall LP, van Twuyver E. Blood transfusion and allograft survival: is mixed chimerisms the solution for tolerance induction in clinical transplantation? Crit Rev Immunol. 1991;10:417-425.
43. Herzog WR, Zanker B, Irschick E, et al. Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft. Transplantation. 1987;43:384-389.
44. Dalman MJ, Shiho O, Page TH, et al. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med. 1991;173:79-87.
45. Iwakoshi NN, Markees TG, Turgeon N, et al. Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol. 2001;167:6623-6630.
46. Yang L, Du TB, Khan Q, et al. Mechanisms of long-term donor-specific allograft survival induced by pretransplant infusion of lymphocytes. Blood. 1998;91:324-330.
47. Madsen JC, Yamada K, Allan JS, et al. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation. 1998;65:304-313.
48. Kawai T, Cosimi AB, Wee SL, et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation. 2002;73:1757-1764.
49. Hamawy MM, Knechtle SJ. Strategies for tolerance induction in non-human primates. Curr Opin Immunol. 1998;10:513-517.
50. Kawai T, Sachs DH, Cosimi AB. Tolerance to vascularized organ allograft in large-animal models. Curr Opin Immunol. 1999;11:516-520.
51. Thomas JM, Carver FM, Kasten-Jolly J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation. 1994;57:101-115.
52. Thomas JM, Carver FM, Cunningham PRG, et al. Kidney allograft tolerance in primates without chronic immunosuppression: the role of veto cells. Transplantation. 1991;51:198-207.
53. Thomas JM, Verbanac KM, Carver FM, et al. Veto cells in transplantation tolerance. Clin Transplant. 1994;8:195-203.
54. Neville DM Jr, Scharf J, et al. A new reagent for the induction of T-cell depletion, antiCD3-CRM9. J Immunother. 1996;19:85-92.
55. Knechtle SJ. Treatment with immunotoxin. Phil Trans R Soc Lond. 2001;356:681-689.
56. Hubbard WJ, Moore JK, Contreras JL, et al. Phenotypic and functional analysis of T-cell recovery after anti-CD3 immunotoxin treatment for tolerance induction in rhesus macaques. Hum Immunol. 2001;62:479-487.
57. Knechtle SJ, Fechner JH, Dong Y, et al. Primate renal transplants using immunotoxin. Surgery. 1998;124:438-447.
58. Feshner JH, Vargo DJ, Geissler EK, et al. Split tolerance induced by immunotoxin in a rhesus kidney allograft model. Transplantation. 1997;63:1339-1345.
59. Thomas JM, Contreras JL, Jiang XL, et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation. 1999;68:1660-1673.
60. Hutchings A, Wu J, Asiedu C, et al. The immune decision toward allograft tolerance in nonhuman primates requires early inhibition of innate immunity and induction of immune regulation. Transplant Immunol. 2003;11:335-344.
61. Hutschings A, Hubbard WJ, Thomas FT, et al. Stealth in transplantation tolerance. Immunol Res. 2002;26:143-152.
62. Contreras JL, Wang PX, Eckhoff DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation. 1998;65:1159-1169.
63. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin (ATG) immunosuppressive activity in a nonhuman primate model. Transplantation. 2001;71:460-468.
64. Previlla X, Sick E, Beauchard S, et al. 6-Methylprednisolone does not impair anti-thymocyte globulin (ATG) immunosuppressive activity in nonhuman primates. Transplant Immunol. 200;19:57-61.
65. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 1998;338:1813-1821.
66. June CH, Bluestone JA, Nadler LM, et al. The B7 and CD28 receptor families. Immunol Today. 1994;15:321-331.
67. Cho CS, Hamawy MM, Knechtle SJ. CD40:CD154 interactions and allograft rejection. Curr Opin Organ Transplant. 2000;5:10-15.
68. Xu H, Montgomery SP, Preston EH, et al. Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol. 2003;170:2776-2782.
69. Renshaw BR, Fanslow WC III, Armitage RJ, et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med. 1994;180:1889-1900.
70. Yanada A, Sayegh MH. The CD154-CD40 costimulatory pathway in transplantation. Transplantation. 2002;73:S36-S39.
71. Vierboom MPM, Osseovoort M, Sick EA, et al. Induction of allograft tolerance through costimulatory blockade: first selection of drugs in vitro. Transplant Immunol. 2003;11:215-222.
72. Kirk AD, Knechtle SJ, Sollinger H, et al. Preliminary results of the use of humanized anti-Cd154 in human renal allotransplantation. Am J Transplant. 2001;1:S191.
73. Kirk AD, Harlan DM, Armstrong NN, et al. CTL-A4 Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997;94:8789-8794.
74. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5:686-693.
75. Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in nonhuman primates. Transplantation. 2001;72:377-384.
76. Montgomery SP, Xu H, Tadaki DK, et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 2002;74:1365-1369.
77. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation. 2002;74:933-940.
78. Kawai T, Abrahamian G, Sogawa H, et al. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Transplant Proc. 2001;33:221-222.
79. Elster EA, Xu H, Tadaki DK, et al. Primate skin allotransplantation with anti-CD154 monotherapy. Transplant Proc. 2001;33:675-676.
80. Elster EA, Xu H, Tadaki DK, et al. Treatment with the humanized CD154-specific monoclonal antibody hu5C8 prevents acute rejection of primary skin allograft in nonhuman primates. Transplantation. 2001;72:1473-1478.
81. Pierson RN 3rd, Chang AC, Blum MG, et al. Prolongation of primate cardiac allograft survival by treatment with anti-CD40 ligand (CD154) antibody. Transplantation. 1999;68:1800-1805.
82. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allograft in rhesus monkeys treated with humanized anti-Cd154. Proc Natl Acad Sci USA. 1999;96:8132-8137.
83. Langer R, Vacanti JP. Tissue engineering. Science. 1993;260:920-926.
84. Elster EA, Blair PJ, Kirk AD. Potential of costimulation-based therapies for composite tissue allotransplantation. Microsurgery. 2000;20:430-434.
85. Daniel RK, Egerszegi EP, Samulack DD, et al. Tissue transplants in primates for upper extremity reconstruction: a preliminary report. J Hand Surg. 1986;11A:1-8.
86. Stark GB, Swartz WM, Narayanan K, et al. Hand transplantation in baboons. Transplant Proc. 1987;19:3968-3971.
87. Stevens HPJD, Hovius SER, Vuzevski VD, et al. Immunolocal aspects of allogeneic partial hand transplantation in the rhesus monkey. Transplant Proc. 1990;22:2006-2008.
88. Stevens HPJD, Hovius SER, Heeney JL, et al. Immunologic aspects and complications of composite tissue allografting for upper extremity re-construction: a study in the rhesus monkey. Transplant Proc. 1991;23:623-625.
89. Gold ME, Randzio J, Kniha H, et al. Transplantation of vascularized composite mandibular allografts in young cynomolgus monkeys. Ann Plast Surg. 1991;26:125-132.
90. Thomas F, Ray P, Thomas JM. Immunological tolerance as an adjunct to allogeneic tissue grafting. Microsurgery. 2000;20:435-440.
91. Petit F, Minns AB, Dubernard JM, et al. Composite tissue allotransplantation and reconstructive surgery: first clinical applications. Ann Surg. 2003;237:19-25.
92. Hettiaratchy S, Randolph MA, Petit F, et al. Composite tissue allotransplantation: a new era in plastic surgery? Br J Plast Surg. 2004;57:381-391.
93. Strome M, Stein J, Esclamado R, et al. Laryngeal transplantation and 40-month follow-up. N Engl J Med. 2001;344:1676-1679.